Evidence map›Paper›PMID 35222403›Full record

ArticleFrontiers in immunology2022

High

Xueting Kong, Jiamian Zheng, Xiaxin Liu, Wandi Wang, Xuan Jiang, Jie Chen, Jing Lai, Zhenyi Jin, Xiuli Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Higher TIGIT+ γδ TFrontiers in immunology · 2024
    Article
  3. Review
  4. Increased PD-1Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xueting KongInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Jiamian ZhengInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Xiaxin LiuInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Wandi WangInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Xuan JiangInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Jie ChenDepartment of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China.
Jing LaiDepartment of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China.
Zhenyi JinInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Xiuli WuInstitute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Jinan University · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heterogeneous T cells in acute myeloid leukemia (AML) have the combinatorial variety generated by different T cell receptors (TCRs). γδ T cells are a distinct subgroup of T cells containing TCRγ ( Methods: In this study, the complementarity-determining region 3 (CDR3) size of Results: We first found that the distribution pattern and clonality of Conclusions: The restriction of

Indexed as

Leukemia, Myeloid, AcuteReceptors, Antigen, T-Cell, gamma-deltaComplementarity Determining RegionsFlow CytometryHumansT-Lymphocyte SubsetsComplementarity Determining RegionsReceptors, Antigen, T-Cell, gamma-deltaacute myeloid leukemiaclonalityprognosisTRGV repertoireγδ T cells

Identifiers

PMID35222403
PMCPMC8866455
OpenAlexW4211117158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.